All Borrelia burgdorferi articles
-
NewsNew research suggests few people get sick after bite from ticks infected with Powassan virus
Scientists have published new findings on Powassan virus, reporting that people bitten by black-legged (or deer) ticks that tested positive for the virus did not show signs or symptoms of disease.
-
NewsScientists pinpoint dominant pathogens in parasitic ticks in grazing areas
A new study maps the bacterium flora and identifies the main pathogens in ticks in grazing areas of Yunnan province in China.
-
NewsProtein found in human sweat may protect against Lyme disease
Researchers also found that a variant of the protein is not as protective against the bacterium and increases susceptibility to the disease.
-
NewsBlack individuals more likely to experience inequities in early diagnosis of Lyme disease
A new study reveals that black patients are more likely to have advanced stages of Lyme disease when clinically diagnosed and also experience a longer time before receiving antibiotic treatment for the condition.
-
News‘Subway map’ of Lyme disease pathways IDs potential treatment targets
Researchers have developed a genome-scale metabolic model of key metabolic activities of the bacterium that causes Lyme disease, successfully identifying two compounds that selectively target routes only used by Lyme disease to infect a host.
-
NewsScientists develop mRNA vaccine against Lyme disease-causing bacteria
An experimental mRNA vaccine provides protection in preclinical animal models against infection from Borrelia burgdorferi, the bacterium that causes Lyme disease, according to new research.
-
NewsWhite-tailed deer blood kills bacteria that causes Lyme disease
The blood of the white-tailed deer kills the corkscrew-shaped bacterium that causes Lyme disease, a potentially debilitating illness.
-
NewsVaccine for Lyme disease one step closer with promising six-month results
A vaccine for Lyme disease is one step closer after Pfizer Inc and Valneva SE reported positive results in their antibody persistence data six months after completing a three-dose or two-dose schdule in children and adults with vaccine candidate VLA15.
